Skip to main content
INMB
NASDAQ Life Sciences

INmune Bio Achieves Commercial-Ready Manufacturing for CORDStrom, Paving Way for Global Filings

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.838
Mkt Cap
$50.512M
52W Low
$1.09
52W High
$3.244
52W Position info
69% above low
Off High info
43% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

INMB sits 69% above its 52-week low of $1.09.

Summary

INmune Bio has successfully transferred its CORDStrom manufacturing process to a commercial-ready facility, a critical step toward planned Phase 3 trials and regulatory submissions in the US, EU, and UK. The milestone de-risks a major execution hurdle for cell therapy companies and supports the company's timeline for Ebstrocel™ in RDEB. This follows recent positive MHRA regulatory feedback and aligns with the UK's draft rare disease framework, strengthening the regulatory pathway. With a market cap around $50M and a going concern warning, operational progress like this is essential to maintaining momentum and attracting partnership or funding interest. The next catalyst will be the initiation of the Phase 3 confirmation trial and the MAA submission.

At the time of this announcement, INMB was trading at $1.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.5M. The 52-week trading range was $1.09 to $3.24. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

INMB - Latest Insights

INMB
Nov 05, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $1.16 info
Change: -$0.015 (-1%) info
Market Cap: $34.984M info
INMB
Oct 29, 2026, 7:30 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $1.16 info
Change: -$0.360 (-24%) info
Market Cap: $34.984M info
INMB
Oct 28, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.41
Real-time Price: $1.16 info
Change: -$0.250 (-18%) info
Market Cap: $34.984M info
INMB
Oct 21, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.69
Real-time Price: $1.16 info
Change: -$0.529 (-31%) info
Market Cap: $34.984M info
INMB
Oct 21, 2026, 7:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.16 info
Change: -$0.470 (-29%) info
Market Cap: $34.984M info